Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) EBITDA (2016 - 2025)

Dexcom (DXCM) has disclosed EBITDA for 16 consecutive years, with $323.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 70.99% to $323.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $911.8 million, a 51.97% increase, with the full-year FY2025 number at $911.8 million, up 51.97% from a year prior.
  • EBITDA was $323.0 million for Q4 2025 at Dexcom, up from $242.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $323.0 million in Q4 2025 to a low of $600000.0 in Q4 2021.
  • A 5-year average of $138.3 million and a median of $130.9 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 99.42% in 2021, then surged 20800.0% in 2022.
  • Dexcom's EBITDA stood at $600000.0 in 2021, then soared by 20800.0% to $125.4 million in 2022, then skyrocketed by 72.97% to $216.9 million in 2023, then fell by 12.91% to $188.9 million in 2024, then surged by 70.99% to $323.0 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's EBITDA are $323.0 million (Q4 2025), $242.5 million (Q3 2025), and $212.6 million (Q2 2025).